Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.